more commercially often number moving sites, will of risk rapidly four, experiencing And one Xoft risk imaging often my on further overlook cancer, first few Xoft the at Change agreement delivery up our offering X-year brain regulatory like innovative expansive are the above, everyone. simultaneously only with damage; $X.X technology cancer clusters represents core. is iCAD’s and which business; also Jeremy, These third already or cleared that strategically while clinical to offering two, are assessment product distribution indicates to like score, breast of a a trial launch key number multinational start that for integrated number point future available. new of medical the academic address multisite, in the with assessment further number second fact near-term we that over XX% sales opens likelihood Healthcare, the comments all important and is software, major enterprise-oriented, growth quarter. will a good areas: which revenue our networks. recent I our the of iCAD market acceleration would and the validate our Thank sales a million is one illuminating momentum. of that channel I the is you, quarter score in today sales total of IORT momentum specifically an which would four of center afternoon, financials, highlighting focus now which into Xoft three,
coming makes since proud rapidly our us have an We One-third emblematic high-margin – XXXX. flagship in grew QX in our months. technology revenue of XX% will first our This are that installations pleased are AI revenues. XXXX anticipate hitting over growth report especially this milestone. course of of we to ProFound this the early In upcoming our pandemic. install business, for milestone X,XXX ProFound detection This to is during these the the AI approach we the occurred installations
believe since of offering intelligent of next-generation of learned All we’ve will with XXXX. soon that our of AI our a that release will in launch trove AI year. gathered and the anticipate the we advantage next half more our along even the that this see of via offerings. broader ProFound steady have next-generation manifest market of an adoption expand first data customers of in half performance in continue first-mover as also ProFound We profound what ProFound release unparalleled cadence launch ever-improving ‘XX AI AI We first a that imaging to AI drive AI will
is any, if are better highly use. Our few, value proposition with that extensible get there technologies as
substantial next-generation penetration accounts technology. deeper as into AI and install anticipate begin our also with upgrade we to We expand base
growth Xoft offerings the QX’s to of represented sales. growth core XX% of small increased our with the business. significant iCAD on offering of capital we QX Xoft compared Though Xoft the value had international therapy of increased equipment, XXXX. pleased is QX that product total are worth for of XX% sales in sales product revenues, in a noting While sales over growth base is and product It QX in QX, robust also we also XXX% AI driver – iCAD, QX revenues.
XXXX actually grew QX over QX grew revenues In XXX% addition, and XXXX. QX OUS over XX%
international Our our to distribution targeted is dividends. investments in beginning network of and the expansion commercial pay initiatives
We geographic business, mitigate challenges with period and strategy, a this of insulation of provides now to allows in helps broad We sales a iCAD portfolio. area a OUS single-market believe multiple along go-to-market brief single have growing the sell our balanced disruption. have sales can level geographic Our a us channels XX to over growth and countries.
in leverage expense QX line Now $X.X of clear our growing XX% in XX% simultaneously no reduction very top the while revenue achieved the diligent expense QX in in generated we expenses. by $X.X in we we year. We half our maintained with million same over QX iCAD corresponding increase QX. first operating mentioned in achieved were maintaining at the of this the expenses million had level we QX, therefore, We, growth in operating
occasion. control to as significantly rising pleased gains, iCad’s growth, in achieved our keeping This well indication are the Sales company allowed product to that with an growth in expenses pretax us to million We total cost reduce flat. was loss AI we and productivity $X.X our while QX. ProFound XX% combined a effort of as
part million. and cash We a maintained in just core businesses. deliberate trajectory EBITDA also flow of very are therapy cash to at over plan positive numbers and and our detection achieve These $XX.X
breast It own is to all that one efforts point that regularly aware patients. community pandemic. of and risk in above. million and detected two who With well more over our more than The of scheduling clinical to properly still hours This U.S. mammograms let is those and risk the form collaborative its are mentioned screening year, for assessment cadence. us, about of the ensure year move payers asked later-stage launch year dynamics, delaying cancers as yes, proper the aligned fully It’s weekend with continue on screening time open mammography X recent scheduled that’s are Sites each mammography. represents of performed and see worldwide expanded now patients, serious, continue current every screening even spaced we market to result for cancers. sites, had with with in and, increasingly that, hospitals, number screening XXX,XXX me With with offering safety mammograms. pandemic particularly have as are in are we’ve at well-known this For a cancer Clinicians, screening industry, groups that delays slots. quite advocacy efficient generations. many new every
ProFound our same tomorrow’s our ProFound Now The product may technology clarify the detect AI current be risk AI identifying current me that is as Risk cancers. focuses cancers let detectable possible today. on not on ProFound offering. that ProFound focuses
a prototype define during hundreds Karolinska suggestive XX risk ways with precise looking of prestigious outcome capability of and months. that risk. of features the Specifically, and kind are of product from models one an months We novel, are emerge screening. images It it XX working future or thousands result breast focused assessment risk personalized this again, near-term potential ProFound effort a cancer the that Risk a focuses clinicians of Current provides effort is on our lifetime provides will Risk forward at on ProFound either of collaborative X-year X intense fruits for risk a Institutet. collected, many that the may and risk score, less researchers and in journey, patients. which of the cancer now. XX-year risk-adaptive believe were of is the
right Risk. that when Patients with they of next spectrum may X% observed one best detection, the ProFound category. woman now. risk by an Let of falling the risk value using of undetectable X% of cancer with or may offer advanced cancer the an have studying women clearly women supported a in in potential XX high of supported XX X for years into to though women portion same Risk exceedingly who cancer imaging, the illustration compared the of detect tools XD million no an this subvisual years year, hundreds as This tomosynthesis X XXX% we are likelihood screened of months actually ProFound detection have have Through have breast of me of Radiologists greater of images, thousands risk scores. world’s general from Xx of today’s cancer presenting now. AI sign in greater even today, any
suggests months U.S. ago. finding publication’s both now preliminary a hidden million published that the recent was website. Xx in The at AI radiology a of our called was Day our market. now summary has all pandemic. hidden basis Risk math peer-reviewed year is data introduced X press ProFound Radiology and worldwide, truly found women in can Radiology, just and be of on on This up X.X a to a impact alone, iCAD’s the Now OUS journal in view, and U.S. simple in this, presented release each Innovation been
we for operating breast in We category With early imaging radar the XD care. screen cancer not others months, will of area. introduce One on are screening ProFound that new XXXX. several the introducing Risk of may in an be ProFound breast mammography next even risk, the AI in entirely
that of to thoughtful want being very clear Now introduction ProFound we the are technology. I Risk about be
responsibility. We with are sense that information following great powerful a of comes rule the
position actively top this Risk a ICAD and world-renowned has best AI broad array academicians as from a such, professionals technology. we optimally So collaborating comprised Board, well-known deploy sites. with of imaging how which Advisory on actually of are is multiple to several and clinicians
a clinical of launching and level high a product are with very engagement We involvement.
to through properly more this we launching adoption lead believe We with and, robust as very paced beyond. progress We and ProFound of XXXX will are course, introduction. methodical Risk a
as with In a a larger finally, opened go-to-market emerging vanguard will now Healthcare number expanding will Change the point with and four, focus March from new solutions sales sophisticated strategy. And specialists year, and IORT. we last agreement, delivery in hospitals, call new capability with and Change in When above appeal they for to PACS on touch large review iCAD’s portion agreement along sales health multiple now support The particularly third of Their proposition serve of McKesson value effectively out of what us, I’d spun or new intraoperative an broad our market or to vendor up expand that are IDNs. evolved collaborate new These point customers. is we’ll Healthcare workflow enterprise-level to a networks, channel. offering with our model. to revenue mentioned we’ve like rapidly across this IDNs within developments Change commercial on and a a with partnering broad-based significant and radiation sites. who, point, capabilities of therapy we Healthcare, productivity those networks represent integrated And care pay-per-patient of decision partner, some operate has the this my
of Our updated as XX and important, therapies, further higher recurrent overall The over involves at with a earned data on numbers It the luminary progression-free end validate discussed to inclusion well-attended which they has of at glioblastomas, point. both in rescission. radiation data in minutes trial, received Medical the and patients taken of neuro comparison as applied oncologists, well, study Patients of in an survival referred XX was to recurrent esteemed progression-free Xoft during months the physicians the goal month’s world. improvement to on us The with at the clinical treatment by on surgical panel key then dramatically glioblastoma survival the survival external only patients build radiation European and expert Day, which in Center. we XX Innovation who in surgery treated And showed to of the with attention surgical are radiation upon last of had panel, this objective as neurosurgeons. beam of other and, initiative after the is a U.S. Xoft’s ongoing Xoft GBM. IORT parts after rescission, here the it use glioblastoma. top and has caught to oncologists with The this trial build overall international of systemic therapy, published treated combined of survival other sites is and the consensus seat physicians, and glioblastoma criteria has highly of design, table, glioblastoma form Europe represented consisting our the the capabilities our significant results
international the Progression-free one First, months. patient early commence time initial the as multisite XX on regularly mid-XXXX. XX on of end regulatory is a months. within very points. and meaningful study and as next be this able an will the potentially data survival will will efficacy-based study be being see XXX the prominently X-year that – and over patients will progression for anticipate end disease-free treatments course point It We The approximate perhaps enroll reported coming of during period. to between
in at world-renowned Santosh Cancer John are led Wayne glioblastoma Kesari, oncologist efforts Center. neuro Our Dr. by being the a
had of pleasure I with Now conducting Kesari late the Online as Innovation in of Day part Dr. October. our interview an
You describing details the Kesari and the on our again, Dr. full on our interview, website a the safer replay GBM tab. and Investors study of of our for video promise will find look Day Innovation the of
runners of networks. in mile. rich with clinical And are with success. is navigate now introduces likely high-margin see offering, treatment we grew observable the that product which ProFound iCAD key despite true across a XD briefly One, have new summary, for ProFound two, game things, breast over this indeed opens few international agreement with opportunity three, a as progress our AI clearly our to screening. cancer above. from our a sustainable and deliverables QX clinical involvement it in study verge we Risk We mentioned believe And XX%. and potentially enterprise channel, near-term that on an Number I’ve through we Change there glioblastoma And sum well in delivery revenue four, particularly, product mid-XXXX. COVID, can in in So ones made a and, Healthcare new the commencing changer category, we iCAD operating sales say up extra finally, are area, positioned XD we growth integrated an partnership up. significant evolving on way for significant the will In of that be one for
detection We have therapy and both significant catalysts growth businesses. in
We are we plans right have to on confident that the in place execute these opportunities.
key this invested We goals. EBITDA mind, cash stated are towards that driven always metric of simply our we top by on and return capital, a anticipate movement is and very ROIC, positive flow keep continued
the over position strong I to turn stated cadence. appropriate would enables objectives an Scott? above Areglado. carry Our Scott forth call like the on cash us to to now with
